Gatifloxacin
drugOn this page
Also known as AM-1155BMS-20658401GatifloGatifloxacin (sesquihydrate)Gatifloxacin anhydrousGatifloxacin hydrateGatifloxacin sesquihydrateGatifloxacineGatifloxacinoNSC-758701PD-135432TequinZymarZymaxidZymerSID26748958SID861394SID104171401SID124888832
Summary
Gatifloxacin (CHEMBL31) is an approved small-molecule antiinfective agent (ATC S01AE06); indicated across 8 conditions including bacterial conjunctivitis and eye infectious disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: S01AE06 (+1 more)
- Indications: 8 conditions
- Clinical trials: 19
- Chemistry: 375.4 Da · C19H22FN3O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL31 |
| Name | Gatifloxacin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5379 |
| ChEBI | CHEBI:5280 |
| ATC | S01AE06, J01MA16 |
| Molecular formula | C19H22FN3O4 |
| Molecular weight | 375.4 |
| InChIKey | XUBOMFCQGDBHNK-UHFFFAOYSA-N |
SMILES: CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
IUPAC name: 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
ChEBI definition: A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Pharmacological roles (ChEBI): antiinfective agent, EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor, antimicrobial agent.
Also known as: AM-1155, BMS-20658401, Gatiflo, Gatifloxacin, Gatifloxacin (sesquihydrate), Gatifloxacin anhydrous, Gatifloxacin hydrate, Gatifloxacin sesquihydrate, Gatifloxacine, Gatifloxacino, NSC-758701, PD-135432
Parent form; salt/anhydrous children: CHEMBL1974188, CHEMBL3764608
Patent coverage: 6,770 distinct patent families (25,151 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 24,781 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lysine-specific demethylase 4E, Streptokinase A, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], DNA gyrase, Mu-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Serine/threonine-protein kinase D3, Polyunsaturated fatty acid lipoxygenase ALOX15, Cruzipain.
Bioactivity
ChEMBL activities: 8 potent at pChembl ≥ 5 of 20 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P0AES4 | 6.3 | IC50 | 500 | nM | CHEMBL_ACT_1695507 |
| P0AES4 | 6.3 | IC50 | 500 | nM | CHEMBL_ACT_1775318 |
| P10520 | 6.17 | EC50 | 668 | nM | CHEMBL_ACT_4937613 |
| P0C1U9 | 5.92 | IC50 | 1200 | nM | CHEMBL_ACT_1695523 |
| CLK4 | 5.4 | Ki | 3981 | nM | CHEMBL_ACT_9691229 |
| CLK2 | 5.1 | Ki | 7943 | nM | CHEMBL_ACT_9507618 |
| PRKD3 | 5.1 | Ki | 7943 | nM | CHEMBL_ACT_9615971 |
| P9WG47 | 5.03 | IC50 | 9400 | nM | CHEMBL_ACT_3551877 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| bacterial conjunctivitis | 4 | MONDO:0006668 | EFO:1000829 |
| eye infectious disorder | 4 | MONDO:0043885 | EFO:1001888 |
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| tuberculosis | 3 | MONDO:0018076 | MONDO:0018076 |
| corneal ulcer | 2 | MONDO:0004577 | MONDO:0004577 |
| cataract | 1 | MONDO:0005129 | MONDO:0005129 |
| osteomyelitis | 0 | MONDO:0005246 | EFO:0003102 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 7 |
| PHASE3 | 4 |
| Not specified | 3 |
| PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00350363 | PHASE4 | COMPLETED | One Hour Preoperative Gatifloxacin |
| NCT00407017 | PHASE4 | COMPLETED | Therapeutic Variables in Cataract Surgery |
| NCT00410891 | PHASE4 | COMPLETED | Topical Antibiotics and Intravitreous Injections |
| NCT00433225 | PHASE4 | COMPLETED | Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation |
| NCT00464438 | PHASE4 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis |
| NCT01421693 | PHASE4 | COMPLETED | Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever |
| NCT03578276 | PHASE4 | COMPLETED | Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen |
| NCT00509873 | PHASE3 | COMPLETED | A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis |
| NCT00518089 | PHASE3 | COMPLETED | A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis |
| NCT01330355 | PHASE3 | TERMINATED | Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis |
| NCT03696342 | PHASE3 | TERMINATED | Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. |
| NCT00396084 | PHASE1/PHASE2 | COMPLETED | Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis |
| NCT00651586 | PHASE2 | COMPLETED | Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers |
| NCT01928693 | PHASE2 | TERMINATED | A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. |
| NCT00824070 | PHASE1 | COMPLETED | Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects |
| NCT00905762 | PHASE1 | COMPLETED | Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation |
| NCT00414011 | Not specified | COMPLETED | Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99) |
| NCT00466570 | Not specified | WITHDRAWN | Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application |
| NCT00569881 | Not specified | COMPLETED | Effect of Topical Fluoroquinolones on Epithelial Wound Healing After PRK |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).